Table of Contents Author Guidelines Submit a Manuscript
Stem Cells International
Volume 2015, Article ID 325652, 7 pages
Clinical Study

Safety of Allogeneic Umbilical Cord Blood Stem Cells Therapy in Patients with Severe Cerebral Palsy: A Retrospective Study

1Department of General Internal Medicine, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou 510120, China
2The School of Medicine, Jinan University, Guangzhou 510632, China
3Shenzhen Beike Cell Engineering Research Institute, Shenzhen 518057, China

Received 3 March 2015; Accepted 28 April 2015

Academic Editor: Thomas Ichim

Copyright © 2015 Mei Feng et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


This retrospective study aimed to assess the safety of patients with severe cerebral palsy (CP), who received allogeneic umbilical cord blood stem cells (UCBSCs) treatment from August 2009 to December 2012 in Guangdong Provincial Hospital of Chinese Medicine. A total of 47 patients with average age of years were evaluated in this study. There was no significant association with allogeneic UCBSCs treatments found in the data of the laboratory index . No casualties occurred. Some adverse events during treatments were found in 26 (55.3%) patients, including fever (42.6%) and vomiting (21.2%). Intrathecal infusion and the ages at the initiation of treatment (≤10 years old) were risk factors for the occurrence of adverse events by logistic regression analysis. However, all adverse events disappeared after symptomatic treatment. No treatment related serious adverse events were found in follow-up visits within 6 months. In conclusion, allogeneic UCBSCs treatment was relatively safe for severe CP patients.